Synthetic Peptide
LGI4 Synthetic Peptide, PEP-0635, from Invitrogen.
The leucine-rich, glioma inactivated gene 4 (LGI4) is a member of the LGI family in which LGI1 is the exemplar. The LGI family consists of four of highly related proteins containing leucine-rich repeats (LRRs) which are highly similar to other transmembrane signaling molecules and receptors. LGI1 has been identified as a candidate tumor suppressor gene for glioma and plays a role in autodominant lateral temporal epilepsy (ADTLE), an epileptic syndrome characterized by focal seizures with predominant auditory symptoms. Despite its high homology with LGI1 and similar pattern of expression, mutations in LGI4 have not been found to be associated with ADTLE. However, the LGI4 gene is located in a region linked to benign familial infantile convulsions. Further study revealed that a GC-to-AT polymorphism was correlated with childhood absence epilepsy. Other studies showed that decreasing LGI4 expression in cultured cells inhibits myelination, indicating that LGI4 may play a role in neural development.
| Marque | Invitrogen |
|---|---|
| Réf. B-LABO | BL-RE-175879 |
| Réf. fabricant | 15378820 |
| Gene ID (Entrez) | 163175 |
| Espèces | Human |
| Méthode de purification | purified |
| Numéro d’adhésion | Q8N135 |
| Nom usuel | Human LGI4 |
| Concentration | 200 μg/mL |
| Contenu et stockage | -20°C |
| Format | Liquid |
| Formule | PBS with 0.1% BSA and 0.02% sodium azide; pH 7.2 |
| À utiliser avec (application) | Blocking Assay, Control |
| Symbole de gène(s) | LGI4 |
| Lyophilisé | No |
| Conservateur | 0.02% sodium azide |
| Type de produit | Peptide |
| Quantité | 50 μg |
| État réglementaire | RUO - research use only |
| Tampon de stockage | PBS |
